Europe's landmark meeting in Gynaecological Oncology, European Society of Gynaecological Oncology (ESGO) 2021, offers professionals a unique opportunity to learn and discuss the latest late-breaking research, new guidelines, practical demonstrations and more.

ESGO 2021

23–25 October 2021 | Prague, Czech Republic
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

🎥 @GeorgetteOni of NHS Nottingham Breast Institute talks on supporting future generations of healthcare professionals

Watch: 👉http://ow.ly/LwxB50LQ3p0👈

@UKONSmember #UKONS2022 #Nursing #OncologyNursing

Reply on Twitter 1598709591365255173Retweet on Twitter 1598709591365255173Like on Twitter 1598709591365255173Twitter 1598709591365255173
Retweet on TwitterVJ Oncology Retweeted
myESMOESMO - Eur. Oncology@myESMO·
December 2, 2022

"As an oncology community, we must rise to the task today of laying the foundations for sustainable, high-quality #CancerCare that will remain accessible tomorrow", @peters_solange said at the Opening Ceremony for #ESMOAsia22.
👉http://ow.ly/XAbU50LTahQ

Reply on Twitter 1598557206957506561Retweet on Twitter 15985572069575065615Like on Twitter 159855720695750656131Twitter 1598557206957506561
Retweet on TwitterVJ Oncology Retweeted
pashtoonkasiPashtoon Kasi MD, MS@pashtoonkasi·
December 2, 2022

🧐TOPAZ-1➡️685 patients.
👇🏾Biomarker analysis👇🏾441 patients.
🛑244 (35.6%)‼️ testing NOT completed?

IDH1 8.8%
HER2 7.9%
FGFR2 3.4%
BRAF 3.6%
BRCA 4.3%
More realistic of real🌍numbers in 1st line.

💡upfront #ctDNA✅ 💯 ➡️you’ll find more. @OncoAlert @curecc #ESMOAsia22 @myESMO https://twitter.com/jdekervel/status/1598599792749600770

Jeroen Dekervel@JDekervel

Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1. Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22 2

Reply on Twitter 1598644651665268736Retweet on Twitter 15986446516652687369Like on Twitter 159864465166526873634Twitter 1598644651665268736
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

#SABCS22 starts in only a couple of days!

Stay tuned right here 👉http://VJOncology.com👈 which will be updated soon on all the latest in #BreastCancer 👩‍⚕‍🎥🎙

@VJOncology @SABCSSanAntonio @AACR #BreastCancer #BCsm #OncoAlert

Reply on Twitter 1598694368269025282Retweet on Twitter 1598694368269025282Like on Twitter 15986943682690252822Twitter 1598694368269025282
Retweet on TwitterVJ Oncology Retweeted
matteolambeMatteo Lambertini, MD PhD@matteolambe·
December 2, 2022

Great comprehensive presentation by super @RebeccaDSing at #ESMOasia22 on #immunotherapy in early triple-negative #BreastCancer: important citation for the recent review by @ElisaAgostinett & the great algorithm for #TNBC treatment by @hoperugo

@OncoAlert @myESMO #bcsm #ImmOnc

4
Reply on Twitter 1598530488737619971Retweet on Twitter 15985304887376199716Like on Twitter 159853048873761997119Twitter 1598530488737619971
Load More

ESGO 2021

23–25 October 2021 | Prague, Czech Republic
Europe's landmark meeting in Gynaecological Oncology, European Society of Gynaecological Oncology (ESGO) 2021, offers professionals a unique opportunity to learn and discuss the latest late-breaking research, new guidelines, practical demonstrations and more.
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

🎥 @GeorgetteOni of NHS Nottingham Breast Institute talks on supporting future generations of healthcare professionals

Watch: 👉http://ow.ly/LwxB50LQ3p0👈

@UKONSmember #UKONS2022 #Nursing #OncologyNursing

Reply on Twitter 1598709591365255173Retweet on Twitter 1598709591365255173Like on Twitter 1598709591365255173Twitter 1598709591365255173
Retweet on TwitterVJ Oncology Retweeted
myESMOESMO - Eur. Oncology@myESMO·
December 2, 2022

"As an oncology community, we must rise to the task today of laying the foundations for sustainable, high-quality #CancerCare that will remain accessible tomorrow", @peters_solange said at the Opening Ceremony for #ESMOAsia22.
👉http://ow.ly/XAbU50LTahQ

Reply on Twitter 1598557206957506561Retweet on Twitter 15985572069575065615Like on Twitter 159855720695750656131Twitter 1598557206957506561
Retweet on TwitterVJ Oncology Retweeted
pashtoonkasiPashtoon Kasi MD, MS@pashtoonkasi·
December 2, 2022

🧐TOPAZ-1➡️685 patients.
👇🏾Biomarker analysis👇🏾441 patients.
🛑244 (35.6%)‼️ testing NOT completed?

IDH1 8.8%
HER2 7.9%
FGFR2 3.4%
BRAF 3.6%
BRCA 4.3%
More realistic of real🌍numbers in 1st line.

💡upfront #ctDNA✅ 💯 ➡️you’ll find more. @OncoAlert @curecc #ESMOAsia22 @myESMO https://twitter.com/jdekervel/status/1598599792749600770

Jeroen Dekervel@JDekervel

Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1. Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22 2

Reply on Twitter 1598644651665268736Retweet on Twitter 15986446516652687369Like on Twitter 159864465166526873634Twitter 1598644651665268736
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

#SABCS22 starts in only a couple of days!

Stay tuned right here 👉http://VJOncology.com👈 which will be updated soon on all the latest in #BreastCancer 👩‍⚕‍🎥🎙

@VJOncology @SABCSSanAntonio @AACR #BreastCancer #BCsm #OncoAlert

Reply on Twitter 1598694368269025282Retweet on Twitter 1598694368269025282Like on Twitter 15986943682690252822Twitter 1598694368269025282
Retweet on TwitterVJ Oncology Retweeted
matteolambeMatteo Lambertini, MD PhD@matteolambe·
December 2, 2022

Great comprehensive presentation by super @RebeccaDSing at #ESMOasia22 on #immunotherapy in early triple-negative #BreastCancer: important citation for the recent review by @ElisaAgostinett & the great algorithm for #TNBC treatment by @hoperugo

@OncoAlert @myESMO #bcsm #ImmOnc

4
Reply on Twitter 1598530488737619971Retweet on Twitter 15985304887376199716Like on Twitter 159853048873761997119Twitter 1598530488737619971
Load More
Importance of real-world data on patient outcomes 2:19
Importance of real-world data on patient outcomes
Vimalanand Prabhu • 26 Oct 2021
Endometrial Cancer Health Outcomes: pembrolizumab for patients with MSI-high endometrial cancer 3:24
Endometrial Cancer Health Outcomes: pembrolizumab for patients with MSI-high endometrial cancer
Vimalanand Prabhu • 26 Oct 2021
Challenges in treatment of obese patients with gynecological malignancies 3:32
Challenges in treatment of obese patients with gynecological malignancies
Maja Pakiz • 24 Oct 2021
Advances in telemedicine for surgeons 4:32
Advances in telemedicine for surgeons
Maja Pakiz • 24 Oct 2021
Telemedicine in the COVID-19 pandemic: advantages and challenges 2:36
Telemedicine in the COVID-19 pandemic: advantages and challenges
Maja Pakiz • 24 Oct 2021
Importance of pathology in gynecological cancer 1:40
Importance of pathology in gynecological cancer
Xavier Matias-Guiu • 25 Oct 2021
KEYNOTE-826: pembrolizumab + chemotherapy vs placebo + chemotherapy for cervical cancer 7:18
KEYNOTE-826: pembrolizumab + chemotherapy vs placebo + chemotherapy for cervical cancer
Nicoletta Colombo • 24 Oct 2021
Breaking bad news in oncology 2:42
Breaking bad news in oncology
Jalid Sehouli • 24 Oct 2021
Gynecological cancers: co-morbidities and best supportive care 2:07
Gynecological cancers: co-morbidities and best supportive care
Jalid Sehouli • 24 Oct 2021
How to improve standard operating procedures for gynecological cancer management 2:19
How to improve standard operating procedures for gynecological cancer management
Jalid Sehouli • 24 Oct 2021
Role of palliative surgery in ovarian cancer 2:08
Role of palliative surgery in ovarian cancer
Jalid Sehouli • 24 Oct 2021
Highlights for pathology at ESGO 0:58
Highlights for pathology at ESGO
Xavier Matias-Guiu • 25 Oct 2021
Pathologic risk stratification of gynecological cancer 0:54
Pathologic risk stratification of gynecological cancer
Xavier Matias-Guiu • 25 Oct 2021
TROPHIMMUN: Results of avelumab for patients with chemo-resistant gestational trophoblastic tumors 3:00
TROPHIMMUN: Results of avelumab for patients with chemo-resistant gestational trophoblastic tumors
Benoit You • 28 Oct 2021
Gestational trophoblastic tumors 0:36
Gestational trophoblastic tumors
Benoit You • 28 Oct 2021
Non-invasive prenatal testing for cancer diagnosis 2:22
Non-invasive prenatal testing for cancer diagnosis
Liesbeth Lenaerts • 29 Oct 2021
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals